These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11284361)

  • 1. Statin therapy--what now?
    Drug Ther Bull; 2001 Mar; 39(3):17-21. PubMed ID: 11284361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin trials in progress: unanswered questions.
    Davidson MH
    Curr Atheroscler Rep; 2001 Jan; 3(1):9-13. PubMed ID: 11123842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
    Svilaas A; Risberg K; Thoresen M; Ose L
    Am J Cardiol; 2000 Dec; 86(11):1250-3, A6. PubMed ID: 11090801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable influence of statins on isoprostanes in hyperlipidemia.
    Sinzinger H; Oguogho A
    Adv Exp Med Biol; 2003; 525():209-12. PubMed ID: 12751770
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
    Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
    Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Pincus J
    Am J Cardiol; 1998 Aug; 82(3):406-7. PubMed ID: 9708683
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
    Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
    J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The hyperlipidemias. Role of various statins].
    Farnier M
    Presse Med; 1999 Nov; 28(36):2002-10. PubMed ID: 10599269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
    Doggrell SA
    Rev Recent Clin Trials; 2006 May; 1(2):143-53. PubMed ID: 18473965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
    Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
    Brandle M; Davidson MB; Schriger DL; Lorber B; Herman WH
    Diabetes Care; 2003 Jun; 26(6):1796-801. PubMed ID: 12766112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
    Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
    Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
    Puccetti L; Bruni F; Bova G; Cercignani M; Palazzuoli A; Console E; Auteri A; Pasqui AL
    Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.